× Key messages Background The study Conclusions Expert commentary
Go back | list
format_size dark_mode
icon-previous icon-next

Background

What do we already know about this topic?

  • Epidemiological studies have demonstrated that patients with type 2 diabetes (T2D) have a 2- to 4-fold increased risk of cardiovascular (CV) disease relative to those without T2D, and CV disease is the leading cause of morbidity and mortality in patients with T2D.
  • Sodium-glucose cotransporter 2 (SGLT2) inhibition effectively lowers blood glucose levels and also brings about other benefits, such as weight loss, low incidence of hypoglycemia, and reduction in blood pressure.
  • Ertugliflozin is an oral, highly selective SGLT2 inhibitor, approved in the United States and European Union to improve glycemic control in adults with T2D.
  • The long-term effects of ertugliflozin on CV and renal outcomes are being assessed in the eValuation of ERTugliflozin effIcacy and Safety CardioVascular Outcomes Trial (VERTIS-CV) (NCT01986881).